Elena Samarova

Elena Samarova

Auto-generated profile, based on publicly available information

Elena Samarova

Affiliation IOTA Pharmaceuticals Ltd, St Johns Innovation Centre, Cambridge, United Kingdom

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LPLavinia-Lorena Pruteanu
Lavinia-Lorena Pruteanu
LKLiliya Kopanitsa
Liliya Kopanitsa
DMDezső Módos
Dezső Módos
EKEdgars Kletnieks
Edgars Kletnieks
ESElena Samarova
Elena Samarova
DBDavid Bailey
David Bailey
Pathway analysis is an informative method for comparing and contrasting drug-induced gene expression in cellular systems. Here, we define the effects of the marine natural product fucoxanthin, separately and in combination with the prototypic phosphatidylinositol 3-kinase (PI3K) inhibitor LY-294002, on gene expression in a well-established human glioblastoma cell system, U87MG. Under conditions which inhibit cell proliferation, LY-294002 and fucoxanthin modulate many pathways in common, including the retinoblastoma, DNA damage, DNA replication and cell cycle pathways. In sharp contrast, we see profound differences in the expression of genes characteristic of pathways such as apoptosis and lipid metabolism, contributing to the development of a differentiated and distinctive drug-induced gene expression signature for each compound. Furthermore, in combination, fucoxanthin synergizes with LY-294002 in inhibiting the growth of U87MG cells, suggesting complementarity in their molecular modes of action and pointing to further treatment combinations. The synergy we observe between the dietary nutraceutical fucoxanthin and the synthetic chemical LY-294002 in producing growth arrest in glioblastoma, illustrates the potential of nutri-pharmaceutical combinations in targeting this challenging disease.